Bayer to invest $2.2B in new Ohio manufacturing complex as FDA CDER opens clinical trial modernization office
read at raps ↗RegulatoryNeutral
Bayer announced plans to spend roughly $2.2 billion on a new manufacturing site in Ohio, aiming to broaden its production capabilities.
The investment is projected to increase capacity and generate employment opportunities in the local community.
At the same time, the FDA's Center for Drug Evaluation and Research has created a dedicated office to modernize and streamline clinical trial processes.
The initiative signals a broader push by regulators to accelerate drug development and improve overall efficiency.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: Bayer plans for $2.2B manufacturing site in Ohio; FDA’s CDER launches clinical trial modernization office”
read at raps ↗
comments(0)
5-min edit window · permanent after that